Inflammatory Markers in Preeclampsia

This study has been completed.

Sponsor:

Information provided by:

Oslo University Hospital

ClinicalTrials.gov Identifier:

NCT01385813

First received: June 29, 2011

Last updated: July 15, 2011

Last verified: May 2011

History of Changes

Tracking Information
First Received Date ^ICMJE	June 29, 2011
Last Updated Date	July 15, 2011
Start Date ^ICMJE	January 1999
Primary Completion Date	May 2004 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT01385813 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Inflammatory Markers in Preeclampsia
Official Title ^ICMJE	Not Provided
Brief Summary	This is an investigation of inflammatory markers in women destined to develop preeclampsia.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case Control Time Perspective: Retrospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	The study comprised 43 pregnant women who developed preeclampsia and 86 pregnant women who fulfilled a normotensive pregnancy. All women were of Caucasian origin, and were nulliparous.
Condition ^ICMJE	Preeclampsia
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Pregnant women who develop preeclampsia pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	129
Completion Date	May 2004
Primary Completion Date	May 2004 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Caucasian origin Exclusion Criteria: Previous diseases e.g. cardiovascular disease, diabetes, hypertension, inflammatory bowel disease, serious organ disease
Gender	Female
Ages	20 Years to 43 Years
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01385813
Other Study ID Numbers ^ICMJE	INFLAMMARPE11
Has Data Monitoring Committee	No
Responsible Party	Professor Lars Mørkrid, University of Oslo
Study Sponsor ^ICMJE	Oslo University Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Oslo University Hospital
Verification Date	May 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top